Real-World Data Back Immunotherapy Boost for Early-Stage Triple-Negative Breast Cancer

One of the most feared diagnoses in oncology may have just received a meaningful vote of confidence from the messy, unfiltered world of everyday medicine. A new systematic review and meta-analysis published in BMC Cancer has pulled together the first comprehensive picture of how pembrolizumab, the immune-checkpoint blockbuster drug, actually performs in routine clinical practice when added to chemotherapy before surgery in patients with early-stage triple-negative breast cancer. The verdict is cautiously encouraging: outside the pristine corridors of randomized trials, the drug appears to deliver many of the benefits clinicians hoped for, with a safety profile that looks manageable, even if the underlying evidence remains far from bulletproof.

Triple-negative breast cancer, often abbreviated TNBC, is the subtype that oncologists dread most. Unlike the majority of breast cancers, its cells lack the estrogen and progesterone receptors that make hormone therapy possible, and they do not overproduce the HER2 protein targeted by drugs such as trastuzumab. That leaves chemotherapy as the historical backbone of treatment, an approach that works for some patients but leaves others facing aggressive disease and limited options. Because TNBC tends to strike younger women and grows quickly, the stakes of getting treatment right before surgery, in the so-called neoadjuvant setting, are unusually high.

The neoadjuvant strategy itself is more than a logistical convenience. Giving systemic therapy before the surgeon’s knife allows clinicians to measure how the tumor responds, and the gold-standard benchmark is the pathologic complete response, or pCR: when pathologists examine the surgically removed tissue and find no residual invasive cancer at all. Achieving pCR is strongly associated with better long-term outcomes, including improved survival, which is why it has become the primary endpoint for most trials of neoadjuvant therapy in this disease. Randomized clinical trials, most prominently the KEYNOTE trials program, have already shown that adding pembrolizumab to neoadjuvant chemotherapy raises pCR rates in early-stage TNBC, and the drug has been approved for this indication in many countries.

But clinical trials, by design, enroll carefully selected patients who often differ from the broad population seen in oncology clinics. Older patients, those with multiple comorbidities, atypical tumor biology, and varied socioeconomic backgrounds are frequently underrepresented. What works in a trial may not translate seamlessly into the real world, where dosing delays, treatment interruptions, and patient heterogeneity are the norm rather than the exception. This gap between trial efficacy and real-world effectiveness is exactly what motivated a team of researchers led by Saad Arsalan Wasti of King Edward Medical University in Lahore, Pakistan, and Fatima Hajj of Lebanese University in Beirut, to systematically hunt down observational studies of pembrolizumab in routine practice.

The methodological machinery behind the new analysis was rigorous. The researchers searched four major biomedical databases, PubMed, Embase, Scopus, and the Cochrane Library, with the search updated through February 2026, capturing both prospective and retrospective cohort studies that compared neoadjuvant pembrolizumab plus chemotherapy against chemotherapy alone in patients with early-stage TNBC. Two reviewers independently screened the studies, extracted the data, and graded methodological quality using the Newcastle-Ottawa Scale, a standard tool for appraising non-randomized research. The pooled estimates were calculated with a random-effects model, which accounts for the statistical heterogeneity that inevitably arises when studies conducted in different settings with different populations are combined. The certainty of the resulting evidence was then formally appraised using the GRADE framework, the international standard for rating how much confidence clinicians can place in a body of evidence.

What emerged from the search was a modest but telling evidence base: five observational studies encompassing 1,501 patients, whose mean ages ranged from 49.5 to 57.8 years. When the data were pooled, the headline finding was striking. Patients who received pembrolizumab alongside their neoadjuvant chemotherapy had roughly one and a half times the likelihood of achieving a pathologic complete response compared with those who received chemotherapy alone, with a risk ratio of 1.52 and a 95 percent confidence interval of 1.29 to 1.80. Because the confidence interval sits entirely above 1.0, the result reaches conventional statistical significance, suggesting the association is unlikely to be a fluke of the small number of studies, even if the precise magnitude remains uncertain.

The surgical implications may prove just as consequential. The analysis found that pembrolizumab-treated patients were less likely to undergo axillary lymph node dissection, the removal of a large number of lymph nodes under the arm, with a risk ratio of 0.65. Axillary dissection is a procedure with real costs: it is a major driver of lymphedema, the chronic and sometimes disabling arm swelling that can follow breast cancer surgery, as well as numbness, shoulder dysfunction, and infection risk. If immunotherapy-driven tumor shrinkage allows more patients to avoid extensive node removal, that represents a tangible quality-of-life dividend beyond the tumor itself. Meanwhile, the review found no clear differences between the two groups in the time to first adjuvant therapy or in postoperative complications, an important signal that adding immunotherapy before surgery does not appear to complicate the surgical journey or delay subsequent treatment.

On the safety front, the picture was consistent with what is known about checkpoint inhibitors. The most frequently reported immune-related adverse events in patients receiving pembrolizumab were thyroid dysfunction and adrenal insufficiency, both reflecting the drug’s tendency to provoke the immune system against the body’s own endocrine organs. These effects are typically manageable with hormone replacement and careful monitoring, but they underscore why patients on checkpoint inhibitors require ongoing surveillance long after the infusion schedule ends. Notably, the analysis did not find a clear increase in perioperative complications, addressing one of the practical concerns that had lingered around delivering immunotherapy in the preoperative window.

Yet the researchers are emphatic that these findings deserve a heavy dose of humility. Using GRADE, they rated the certainty of evidence as very low for every outcome examined. The reasons are structural: observational studies are inherently vulnerable to confounding, selection bias, and residual imbalances between treatment groups, since patients who receive the newer drug may differ systematically from those who do not in ways that no statistical adjustment fully captures. Sample sizes were relatively small, follow-up durations varied, adverse-event reporting was inconsistent across studies, and the review was restricted to published data, meaning individual patient records were unavailable for deeper subgroup or adjustment analyses. The authors also registered the review prospectively on the Open Science Framework, a transparency measure that helps guard against outcome-switching but cannot compensate for the limitations of the underlying studies.

So where does this leave patients and clinicians? The most honest reading is that real-world experience so far mirrors the randomized trial evidence: pembrolizumab added to neoadjuvant chemotherapy in early-stage triple-negative breast cancer appears to boost the chances of a complete pathologic response, may spare some women extensive lymph node surgery, and does not obviously worsen surgical outcomes, all while carrying a predictable immune-related toxicity profile. That consistency across two very different kinds of evidence is reassuring, and for a disease with historically few targeted options, it matters. But the authors themselves caution that these results should not be interpreted as definitive. What the field needs next, they argue, is continued safety surveillance and well-designed comparative studies that can bring the rigor of randomization, or at least far more sophisticated adjustment, to the realities of routine care. Until then, the real-world story of pembrolizumab in TNBC remains a promising draft rather than a finished chapter, one that thousands of women and their physicians will be watching closely as the evidence matures.

Subject of Research: Real-world effectiveness and safety of neoadjuvant pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer

Article Title: Real-world effectiveness and safety of neoadjuvant pembrolizumab in early-stage triple-negative breast cancer: a systematic review and meta-analysis

Article References: Wasti, S. A., Gill, S., Jamshed, A., Noor, M., Gill, N., Wasti, A., Waqas, S., Qayyum, T., Joseph, Y., Amin, F., Mohib, K., Khalid, A., Iqbal, M. U., Ur Rehman, M. S., & Hajj, F. (2026). Real-world effectiveness and safety of neoadjuvant pembrolizumab in early-stage triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-17076-x

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17076-x

Keywords: triple-negative breast cancer, pembrolizumab, neoadjuvant therapy, immunotherapy, pathologic complete response, systematic review, meta-analysis, real-world evidence, immune-related adverse events, axillary lymph node dissection, breast cancer surgery, oncology